Treatment of Lateral Epicondylitis With Platelet-Rich Plasma, Glucocorticoid, or Saline A Randomized, Double-Blind, Placebo-Controlled Trial

被引:231
|
作者
Krogh, Thoger Persson [1 ]
Fredberg, Ulrich [1 ]
Stengaard-Pedersen, Kristian [1 ]
Christensen, Robin [1 ]
Jensen, Pia [1 ]
Ellingsen, Torkell [1 ]
机构
[1] Reg Hosp Silkeborg, Ctr Diagnost, DK-8600 Silkeborg, Denmark
来源
AMERICAN JOURNAL OF SPORTS MEDICINE | 2013年 / 41卷 / 03期
关键词
lateral humeral epicondylitis; tendinopathy; growth factors; platelet-rich plasma; glucocorticoid; ultrasonography; injection therapy; pain; randomized controlled trial; POWER DOPPLER ULTRASOUND; UPPER-LIMB DISORDERS; CHRONIC TENNIS ELBOW; CORTICOSTEROID INJECTION; MEDIAL EPICONDYLITIS; SPORTS-MEDICINE; CLINICAL-TRIAL; TENDON REPAIR; BASE-LINE; FOLLOW-UP;
D O I
10.1177/0363546512472975
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Lateral epicondylitis (LE) is a common musculoskeletal disorder for which an effective treatment strategy remains unknown. Purpose: To examine whether a single injection of platelet-rich plasma (PRP) is more effective than placebo (saline) or glucocorticoid in reducing pain in adults with LE after 3 months. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: A total of 60 patients with chronic LE were randomized (1: 1: 1) to receive either a blinded injection of PRP, saline, or glucocorticoid. The primary end point was a change in pain using the Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire at 3 months. Secondary outcomes were ultrasonographic changes in tendon thickness and color Doppler activity. Results: Pain reduction at 3 months (primary end point) was observed in all 3 groups, with no statistically significant difference between the groups; mean differences were the following: glucocorticoid versus saline: -3.8 (95% CI, -9.9 to 2.4); PRP versus saline: -2.7 (95% CI, -8.8 to 3.5); and glucocorticoid versus PRP: -1.1 (95% CI, -7.2 to 5.0). At 1 month, however, glucocorticoid reduced pain more effectively than did both saline and PRP; mean differences were the following: glucocorticoid versus saline: -8.1 (95% CI, -14.3 to -1.9); and glucocorticoid versus PRP: -9.3 (95% CI, -15.4 to -3.2). Among the secondary outcomes, at 3 months, glucocorticoid was more effective than PRP and saline in reducing color Doppler activity and tendon thickness. For color Doppler activity, mean differences were the following: glucocorticoid versus PRP: -2.6 (95% CI, -3.1 to -2.2); and glucocorticoid versus saline: -2.0 (95% CI, -2.5 to -1.6). For tendon thickness, mean differences were the following: glucocorticoid versus PRP: -0.5 (95% CI, -0.8 to -0.2); and glucocorticoid versus saline: -0.8 (95% CI, -1.2 to -0.5). Conclusion: Neither injection of PRP nor glucocorticoid was superior to saline with regard to pain reduction in LE at the primary end point at 3 months. However, injection of glucocorticoid had a short-term pain-reducing effect at 1 month in contrast to the other therapies. Injection of glucocorticoid in LE reduces both color Doppler activity and tendon thickness compared with PRP and saline.
引用
收藏
页码:625 / 635
页数:11
相关论文
共 50 条
  • [31] Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
    Mandrioli, Jessica
    D'Amico, Roberto
    Zucchi, Elisabetta
    De Biasi, Sara
    Banchelli, Federico
    Martinelli, Ilaria
    Simonini, Cecilia
    Lo Tartaro, Domenico
    Vicini, Roberto
    Fini, Nicola
    Gianferrari, Giulia
    Pinti, Marcello
    Lunetta, Christian
    Gerardi, Francesca
    Tarlarini, Claudia
    Mazzini, Letizia
    De Marchi, Fabiola
    Scognamiglio, Ada
    Soraru, Gianni
    Fortuna, Andrea
    Lauria, Giuseppe
    Dalla Bella, Eleonora
    Caponnetto, Claudia
    Meo, Giuseppe
    Chio, Adriano
    Calvo, Andrea
    Cossarizza, Andrea
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [32] Multiple platelet-rich plasma injections are superior to single PRP injections or saline in osteoarthritis of the knee: the 2-year results of a randomized, double-blind, placebo-controlled clinical trial
    Yurtbay, Alparslan
    Say, Ferhat
    Cinka, Hikmet
    Ersoy, Ahmet
    ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2022, 142 (10) : 2755 - 2768
  • [33] Multiple platelet-rich plasma injections are superior to single PRP injections or saline in osteoarthritis of the knee: the 2-year results of a randomized, double-blind, placebo-controlled clinical trial
    Alparslan Yurtbay
    Ferhat Say
    Hikmet Çinka
    Ahmet Ersoy
    Archives of Orthopaedic and Trauma Surgery, 2022, 142 : 2755 - 2768
  • [34] Double-Blind, Placebo-Controlled Pilot Study on the Use of Platelet-Rich Plasma in Women With Female Androgenetic Alopecia
    Alves, Rubina
    Grimalt, Ramon
    DERMATOLOGIC SURGERY, 2018, 44 (01) : 132 - 133
  • [35] DEXAMETHASONE FOR THE TREATMENT OF DEPRESSION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL
    ARANA, GW
    SANTOS, AB
    LARAIA, MT
    MCLEODBRYANT, S
    BEALE, MD
    RAMES, LJ
    ROBERTS, JM
    DIAS, JK
    MOLLOY, M
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (02): : 265 - 267
  • [36] Double-Blind, Placebo-Controlled Pilot Study on the Use of Platelet-Rich Plasma in Women With Female Androgenetic Alopecia
    Puig, Carlos J.
    Reese, Robert
    Peters, Michelle
    DERMATOLOGIC SURGERY, 2016, 42 (11) : 1243 - 1247
  • [37] A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania
    Van Ameringen, Michael
    Mancini, Catherine
    Patterson, Beth
    Bennett, Mark
    Oakman, Jonathan
    JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (10) : 1336 - 1343
  • [38] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [39] PLATELET-RICH PLASMA INJECTION FOR THE TREATMENT OF STRESS URINARY INCONTINENCE IN FEMALES: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Ashton, Leah
    Nataksuka, Hannah
    Johnson, Colin
    Kenne, Kimberly
    Kreder, Karl
    Kruse, Ryan
    Ten Eyck, Patrick
    Takacs, Elizabeth
    Vollstedt, Annah
    JOURNAL OF UROLOGY, 2024, 211 (05): : E383 - E383
  • [40] A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis
    Baker, Matthew C.
    Horomanski, Audra
    Wang, Yiwen
    Liu, Yuhan
    Parsafar, Shima
    Fairchild, Robert
    Mooney, Joshua J.
    Raj, Rishi
    Witteles, Ronald
    Genovese, Mark C.
    RHEUMATOLOGY, 2023, : 1297 - 1304